Answers are grounded in this paper and cite their sources.
PURPOSE: circulating tumor DNA (ctDNA) analysis in the two phase III randomized trials of fulvestrant versus exemestane. EXPERIMENTAL DESIGN: mutation status on progression-free (PFS) and overall survival (OS) in a combined analysis of both studies. CONCLUSIONS: mutations in baseline ctDNA is associated with inferior PFS and OS in patients treated with exemestane versus fulvestrant.
No takes yet. Share an insight, caveat, or question.
Turner et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: